Cited by 173Gout, Hyperuricemia, Uric AcidBlood Pressure and Hypertension StudiesSodium Intake and Health

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis

Open access

Agarwal, Vikram, Hans, Nidhi, Messerli, Franz H.·2013·The Journal of Clinical Hypertension

DOI 10.1111/j.1751-7176.2012.00701.xPMC PMC8033809

Open this paper in CoChat — free account

Abstract

J Clin Hypertens (Greenwich). 2013; 15:435–442 ©2012 Wiley Periodicals, Inc. Allopurinol is a potent xanthine oxidase inhibitor that is used in hyperuricemic patients to prevent gout. It has also been shown to decrease cardiovascular complications in a myriad of cardiovascular conditions. However, studies have reported conflicting evidence on its effects on blood pressure (BP). A systematic review was conducted using Medline, PubMed, Embase, and the Cochrane Library for all the longitudinal studies that assessed the efficacy of allopurinol on systolic and diastolic BP. A total of 10 clinical studies with 738 participants were included in the analysis. Compared with the control group, systolic BP decreased by 3.3 mm Hg (95% confidence interval [CI], 1.4–5.3 mm Hg; P=.001) and diastolic BP decreased by 1.3 mm Hg (95% CI, 0.1–2.5 mm Hg; P=.03) in patients treated with allopurinol. When analysis was restricted to the higher‐quality randomized controlled trials, similar changes in systolic and diastolic BPs were found: 3.3 mm Hg (95% CI, 0.8–5.8 mm Hg; P<.001) and 1.4 mm Hg (95% CI, 0.1–2.7 mm Hg; P=.04), respectively. Allopurinol is associated with a small but significant reduction in BP. This effect can be potentially exploited to aid in controlling BP in hypertensive patients with hyperuricemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1751-7176.2012.00701.x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,467
Reported Methodologic Quality and Discrepancies between Large and Small Randomized Trials in Meta-Analyses
Gluud, L. L., Villumsen, J., & Gluud, C. N. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,266
Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study
Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-1-199907060-00003 · Cited by 1,282

Show all 33 references

Sorted by citations

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Uric Acid and Oxidative Stress—Relationship with Cardiovascular, Metabolic, and Renal Impairment
Gherghina, M.-E., Peride, I., Ţigliş, M., Neagu, T. P., Niculae, A., & Checheriţă, I. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063188 · Cited by 505
Uric acid and cardiovascular disease
Ndrepepa, G. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.046 · Cited by 512
Serum uric acid and the risk of cardiovascular and renal disease
Borghi, C., Rosei, E. A., Bardin, T., Dawson, J., Dominiczak, A. F., Kielstein, J. T., Manolis, A. J., Pérez-Ruiz, F., & Mancia, G. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000701 · Cited by 477
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Borghi, C., Agabiti‐Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redón, J., Stack, A. G., & Tsioufis, K. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.006 · Cited by 462
Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies
Li, X., Meng, X., Timofeeva, M. N., Tzoulaki, I., Tsilidis, K. K., Ioannidis, J. P. A., Campbell, H. J., & Τheodoratou, E. (2017) · BMJ · doi:10.1136/bmj.j2376 · Cited by 402
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
Bardin, T., & Richette, P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0890-9 · Cited by 387
Oxidative Stress and Human Hypertension: Vascular Mechanisms, Biomarkers, and Novel Therapies
Montezano, A. C. I., Dulak-Lis, M. G., Tsiropoulou, S., Harvey, A., Briones, A. M., & Touyz, R. M. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.008 · Cited by 324
Improving cardiovascular and renal outcomes in gout: what should we target?
Richette, P., Pérez-Ruiz, F., Doherty, M., Jansen, T., Nuki, G., Pascual, E., Punzi, L., So, A. K.-L., & Bardin, T. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.124 · Cited by 228
Gut bacterial metabolism contributes to host global purine homeostasis
Kasahara, K., Kerby, R. L., Zhang, Q., Pradhan, M., Mehrabian, M., Lusis, A. J., Bergström, G. M. L., Bäckhed, F., & Rey, F. E. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.011 · Cited by 237
The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality
Gustafsson, D., & Unwin, R. J. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-164 · Cited by 212
Oxidative Stress and Antioxidant Treatments in Cardiovascular Diseases
Wang, W., & Kang, P. M. (2020) · Antioxidants · doi:10.3390/antiox9121292 · Cited by 199
Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
Bredemeier, M., Lopes, L. M., Eisenreich, M. A., Hickmann, S., Bongiorno, G. K., Davila, R., Morsch, A., Stein, F. D. S., & Campos, G. G. D. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0757-9 · Cited by 187
Uric acid and the cardio‐renal effects of SGLT2 inhibitors
Bailey, C. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13670 · Cited by 187
Uric Acid and Hypertension: a Review of Evidence and Future Perspectives for the Management of Cardiovascular Risk
Borghi, C., Agnoletti, D., Cicero, A. F. G., Lurbe, E., & Virdis, A. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.17956 · Cited by 192
Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies
Zuo, T., Liu, X., Jiang, L., Mao, S., Yin, X. H., & Guo, L. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0379-z · Cited by 176
Hyperuricemia, Cardiovascular Disease, and Hypertension
Kuwabara, M. (2015) · Pulse · doi:10.1159/000443769 · Cited by 175
Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis
Kushiyama, A., Nakatsu, Y., Matsunaga, Y., Yamamotoya, T., Mori, K., Ueda, K., Inoue, Y., Sakoda, H., Fujishiro, M., Ono, H., et al. (2016) · Mediators of Inflammation · doi:10.1155/2016/8603164 · Cited by 188
Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP
Johnson, T. A., Jinnah, H. A., & Kamatani, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00098 · Cited by 151
In vivo anti-hyperuricemic and xanthine oxidase inhibitory properties of tuna protein hydrolysates and its isolated fractions
He, W., Su, G., Sun‐Waterhouse, D., Waterhouse, G. I. N., Zhao, M., & Yang, L. (2018) · Food Chemistry · doi:10.1016/j.foodchem.2018.08.057 · Cited by 132
Allopurinol and Cardiovascular Outcomes in Adults With Hypertension
MacIsaac, R. L., Salatzki, J., Higgins, P., Walters, M. R., Padmanabhan, S., Dominiczak, A. F., Touyz, R. M., & Dawson, J. (2016) · Hypertension · doi:10.1161/hypertensionaha.115.06344 · Cited by 124
Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs
Alani, H. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.156 · Cited by 119
Renal Oxidative Stress Induced by Long-Term Hyperuricemia Alters Mitochondrial Function and Maintains Systemic Hypertension
Cristóbal-García, M., García‐Arroyo, F. E., Tapia, E., Osorio‐Alonso, H., Arellano-Buendía, A. S., Madero, M., Rodríguez‐Iturbe, B., Pedraza‐Chaverrí, J., Correa, F., Zazueta, C., et al. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/535686 · Cited by 114
Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial
McMullan, C. J., Borgi, L., Fisher, N. D. L., Curhan, G. C., & Forman, J. P. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10771016 · Cited by 112
Hyperuricemia: An Intriguing Connection to Metabolic Syndrome, Diabetes, Kidney Disease, and Hypertension
Vareldzis, R., Perez, A., & Reisin, E. (2024) · Current Hypertension Reports · doi:10.1007/s11906-024-01295-3 · Cited by 102
Allopurinol as a therapeutic option in cardiovascular disease
Okafor, O., Farrington, K., & Gorog, D. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.12.004 · Cited by 102
MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank
Li, X., Meng, X., Spiliopoulou, A., Timofeeva, M. N., Wei, W., Gifford, A., Shen, X., He, Y., Varley, T., McKeigue, P., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212534 · Cited by 96
Hyperuricemia and Hypertension: Links and Risks
Stewart, D. J., Langlois, V., & Noone, D. G. (2019) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s184685 · Cited by 118
Update in uric acid, hypertension, and cardiovascular diseases
Kuwabara, M., Kodama, T., Ae, R., Kanbay, M., Andrés-Hernando, A., Borghi, C., Hisatome, I., & Lanaspa, M. A. (2023) · Hypertension Research · doi:10.1038/s41440-023-01273-3 · Cited by 92
Uric acid and hypertension
Becker, B. D., Borghi, C., Burnier, M., & van de Borne, P. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001980 · Cited by 85
Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk
Borghi, C., Tykarski, A., Widecka, K., Filipiak, K. J., Domienik‐Karłowicz, J., Kostka-Jeziorny, K., Varga, A., Jaguszewski, M. J., Narkiewicz, K., & Mancia, G. (2018) · Cardiology Journal · doi:10.5603/cj.2018.0116 · Cited by 84
Uric acid induced inflammatory responses in endothelial cells via up-regulating(pro)renin receptor
Yang, X., Gu, J., Lv, H., Li, H., Cheng, Y., Liu, Y., & Jiang, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.129 · Cited by 79
Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis
Qu, L., Jiang, H., & Chen, J. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1243803 · Cited by 80
The Role of Antioxidants in the Therapy of Cardiovascular Diseases—A Literature Review
Młynarska, E., Hajdys, J., Czarnik, W., Fularski, P., Leszto, K., Majchrowicz, G., Lisińska, W., Rysz, J., & Franczyk, B. (2024) · Nutrients · doi:10.3390/nu16162587 · Cited by 89
Pharmacotherapy for hyperuricemia in hypertensive patients
Gois, P. H. F., & Souza, E. R. D. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008652.pub3 · Cited by 76
Allopurinol Initiation and Change in Blood Pressure in Older Adults With Hypertension
Beattie, C. J., Fulton, R. L., Higgins, P., Padmanabhan, S., McCallum, L., Walters, M. R., Dominiczak, A. F., Touyz, R. M., & Dawson, J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03953 · Cited by 67
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution
Stamp, L. K., & Dalbeth, N. (2016) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2016.07.015 · Cited by 65
Bariatric surgery in severely obese adolescents improves major comorbidities including hyperuricemia
Oberbach, A., Neuhaus, J., Inge, T. H., Kirsch, K., Schlichting, N. S., Blüher, S., Kullnick, Y., Kügler, J., Baumann, S., & Till, H. (2013) · Metabolism · doi:10.1016/j.metabol.2013.11.012 · Cited by 62
Hypertension: Current trends and future perspectives
Hunter, P. G., Chapman, F. A., & Dhaun, N. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14825 · Cited by 79
Identification and Anti-Hyperuricemic Activity of Xanthine Oxidase Inhibitory Peptides from Pacific White Shrimp and Swimming Crab Based on Molecular Docking Screening
Mao, Z., Jiang, H., & Mao, X. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c07881 · Cited by 51
Uric Acid and Arterial Stiffness
Albu, A., Para, I., & Porojan, M. D. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s232033 · Cited by 50
Serum uric acid as a predictor of future hypertension: Stratified analysis based on body mass index and age
Yokoi, Y., Kondo, T., Okumura, N., Shimokata, K., Osugi, S., Maeda, K., & Murohara, T. (2016) · Preventive Medicine · doi:10.1016/j.ypmed.2016.07.007 · Cited by 45
Serum Uric Acid Level, Longitudinal Blood Pressure, Renal Function, and Long-Term Mortality in Treated Hypertensive Patients
Dawson, J., Jeemon, P., Hetherington, L., Judd, C., Hastie, C. E., Schulz, C., Sloan, W. T., Muir, S. W., Jardine, A. G., McInnes, G. T., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.00859 · Cited by 43
Hyperuricemia and the Prognosis of Hypertensive Patients: A Systematic Review and Meta‐Analysis
Qin, T., Zhou, X., Wang, J., Wu, X., Li, Y., Wang, L., Huang, H., & Li, J. (2016) · Journal of Clinical Hypertension · doi:10.1111/jch.12855 · Cited by 43
Urate crystal deposition, prevention and various diagnosis techniques of GOUT arthritis disease: a comprehensive review
Parthasarathy, P., & Vivekanandan, S. (2018) · Health Information Science and Systems · doi:10.1007/s13755-018-0058-9 · Cited by 41
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
Kario, K., Nishizawa, M., Kiuchi, M., Kiyosue, A., Tomita, F., Ohtani, H., Abe, Y., Kuga, H., Miyazaki, S., Kasai, T., et al. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14153 · Cited by 40
Age-differential association between serum uric acid and incident hypertension
Lee, S. W., Kim, H. C., Nam, C. M., Lee, H., Ahn, S. V., Oh, Y. A., & Suh, I. (2018) · Hypertension Research · doi:10.1038/s41440-018-0168-4 · Cited by 39
Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout
Johnson, R. J., Choi, H. K., Yeo, A. E. T., & Lipsky, P. E. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12727 · Cited by 39
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes
Kaul, S., Gupta, M., Bandyopadhyay, D., Hajra, A., DEEDWANIA, P. C., Roddy, E., Mamas, M. A., Klein, A. L., Lavie, C. J., Fonarow, G. C., et al. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00459-1 · Cited by 38
Crystal-proven Gout and Characteristic Gout Severity Factors Are Associated with Cardiovascular Disease
Disveld, I. J. M., Fransen, J., Rongen, G. A. P. J. M., Kienhorst, L. B. E., Zoakman, S., Janssens, H., & Janssen, M. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170555 · Cited by 36
Allopurinol blocks aortic aneurysm in a mouse model of Marfan syndrome via reducing aortic oxidative stress
Rodríguez-Rovira, I., Arce, C., Rycke, K. D., Pérez, B., Carretero, A., Arbonés, M., Teixidó‐Turà, G., Gómez‐Cabrera, M. C., Campuzano, V., Jiménez‐Altayó, F., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.11.001 · Cited by 34
Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme
Rullo, R., Cerchia, C., Nasso, R., Romanelli, V., Vendittis, E. D., Masullo, M., & Lavecchia, A. (2023) · Antioxidants · doi:10.3390/antiox12040825 · Cited by 37
Xanthine oxidase gene variants and their association with blood pressure and incident hypertension
Scheepers, L. E. J. M., Wei, F.-F., Stolarz‐Skrzypek, K., Malyutina, S. K., Tikhonoff, V., Thijs, L., Salvi, E., Barlassina, C., Filipovský, J., Casiglia, E., et al. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001077 · Cited by 34
Cardiac and renal protective effects of urate-lowering therapy
Richette, P., Latourte, A., & Bardin, T. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex432 · Cited by 34
Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry
Yoshida, S., Kurajoh, M., Fukumoto, S., Murase, T., Nakamura, T., Yoshida, H., Hirata, K., Inaba, M., & Emoto, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-61463-8 · Cited by 34
Uric acid and risk of pre-eclampsia: results from a large case–control study and meta-analysis of prospective studies
Mejía, C. C. C., Quintero-Lesmes, D. C., Bautista‐Niño, P. K., Guío, E., Páez, M. C., Beltrán, M., Williams, D. J., Gray, K. J., Casas, J. P., & Serrano, N. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-29651-4 · Cited by 33
Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
Akimoto, T., Morishita, Y., Ito, C., Iimura, O., Tsunematsu, S., Watanabe, Y., Kusano, E., & Nagata, D. (2014) · Drug Target Insights · doi:10.4137/dti.s16524 · Cited by 35
Prevalence of Hyperuricemia and the Relationship Between Serum Uric Acid and Hypertension in New Onset Diabetic Patients: A Cross-Sectional Indian Study
Sk, S., Singh, R., Singh, S. K., Iquebal, M. A., Jaiswal, S., & Singh, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s363311 · Cited by 31
Gout and hyperuricaemia: modifiable cardiovascular risk factors?
Burnier, M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1190069 · Cited by 31
“Repurposing” of Xanthine Oxidoreductase as a Nitrite Reductase: A New Paradigm for Therapeutic Targeting in Hypertension
Khambata, R. S., Ghosh, S. M., & Ahluwalia, A. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6254 · Cited by 30
Consensus on patients with hyperuricemia and high cardiovascular risk treatment
Чазова, И. Е., Zhernakova, Y. V., Кislyak, O. A., Nedogoda, S. V., Podzolkov, V. I., Ощепкова, Е. В., Medvedeva, I. V., Mironova, O. I., & Blinova, N. V. (2019) · Systemic Hypertension · doi:10.26442/2075082x.2019.4.190686 · Cited by 31
Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid‐induced hyperuricemia rats
Dera, A. A., Rajagopalan, P., Alfhili, M. A., Ahmed, I., & Chandramoorthy, H. C. K. (2019) · BioFactors · doi:10.1002/biof.1590 · Cited by 30
Uric acid: association with rate of renal function decline and time until start of dialysis in incident pre-dialysis patients
the PREPARE-2 study group, Nacak, H., van Diepen, M., de Goeij, M. C. M., Rotmans, J. I., & Dekker, F. W. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-91 · Cited by 28
Structure–activity relationships of fraxamoside as an unusual xanthine oxidase inhibitor
Vitale, R. M., Antenucci, L., Gavagnin, M., Raimo, G., & Amodeo, P. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1252758 · Cited by 28
Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases
Fiori, E., Fazio, L. D., Pidone, C., Perone, F., Tocci, G., Battistoni, A., Barbato, E., Volpe, M., Gallo, G., & the Young Group of The Italian Society of Cardiovascular Prevention (SIPREC) (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003807 · Cited by 30
Allopurinol Is an Independent Determinant of Improved Arterial Stiffness in Chronic Kidney Disease: A Cross-Sectional Study
Ng, K. P., Stringer, S. J., Jesky, M., Yadav, P., Athwal, R., Dutton, M., Ferro, C. J., & Cockwell, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091961 · Cited by 27
Pharmacotherapy for hyperuricaemia in hypertensive patients
Gois, P. H. F., & Souza, E. R. D. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008652.pub4 · Cited by 27
Novel peptides with xanthine oxidase inhibitory activity identified from macadamia nuts: integrated in silico and in vitro analysis
Zhao, L., Ai, X., Pan, F., Zhao, L., Zhao, L., Cai, S., & Tang, X. (2022) · European Food Research and Technology · doi:10.1007/s00217-022-04028-5 · Cited by 25
Selective fishing and analysis of xanthine oxidase binders from two Fabaceae species by coupling enzyme functionalized core–shell magnetic nanoparticles with HPLC–MS
Liu, L., Shi, S., Zhao, H., Yu, J., Jiang, X., & Chen, X. (2013) · Journal of Chromatography B · doi:10.1016/j.jchromb.2013.11.053 · Cited by 23
Weight Loss Mediated Reduction in Xanthine Oxidase Activity and Uric Acid Clearance in Adolescents with Severe Obesity
Tam, H. K., Kelly, A. S., Fox, C. K., Nathan, B. M., & Johnson, L. A. (2016) · Childhood Obesity · doi:10.1089/chi.2015.0051 · Cited by 22
Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy
Елисеев, М. С., & Novikova, A. M. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.05.000232 · Cited by 22
Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022
Чазова, И. Е., Zhernakova, Y. V., Кislyak, O. A., Podzolkov, V. I., Ощепкова, Е. В., Mironova, O. Y., & Blinova, N. V. (2022) · Systemic Hypertension · doi:10.38109/2075-082x-2022-1-5-22 · Cited by 22
Cardiovascular disease and uric acid: is the not-so-innocent bystander becoming a true culprit and does the US black box warning for febuxostat indicate that not all uric acid lowering is beneficial?
Messerli, F. H., & Burnier, M. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz199 · Cited by 21
Self-citation
Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
Chazova, I. E., Михайловна, Ч. Н., Blinova, N. V., Владимировна, А. А., Alekseeva, T. A., Ambatiello, L. G., Balanova, Y. А., Bragina, A. E., Danilov, N. M., Drapkina, O. M., et al. (2024) · Systemic Hypertension · doi:10.38109/2075-082x-2024-4-5-109 · Cited by 23
Virtual screening and directional preparation of xanthine oxidase inhibitory peptides derived from hemp seed protein
Huang, X.-N., Liao, J., Shi, P., Pei, X., & Wang, C. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2023.9250047 · Cited by 20
Allopurinol Protects against Ischemia/Reperfusion-Induced Injury in Rat Urinary Bladders
Shin, J.-H., Chun, K. S., Na, Y. G., Song, K.-H., Kim, S. I., Lim, J.-S., & Kim, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/906787 · Cited by 19
Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout
Richette, P., Frazier, A., & Bardin, T. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000149 · Cited by 18
Screening and identification of selenium-enriched purine-lowering Lactobacillus plantarum and Lactococcus lactis with high stress tolerance and antioxidant capacity
Liao, J., Tan, C.-Y., Liang, L., Luo, Y.-Z., Li, H., Chen, Y.-Y., Pei, X., & Wang, C. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104439 · Cited by 19
Effect of Xanthine Oxidase Inhibition on Arterial Stiffness in Patients With Chronic Heart Failure
Alem, M. M., Alshehri, A., Cahusac, P., & Walters, M. R. (2018) · Clinical Medicine Insights Cardiology · doi:10.1177/1179546818779584 · Cited by 16
Association of serum xanthine oxidase levels with hypertension: a study on Bangladeshi adults
Miah, R., Fariha, K. A., Sony, S. A., Ahmed, S., Hasan, M., Mou, A. D., Barman, Z., Hasan, A., Mohanto, N. C., & Ali, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-26341-5 · Cited by 17
Comparative Safety of Gout Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Clone-censor-weight Target Trial Emulation Approach
Yoshida, K., Liu, J., Desai, R. J., Glynn, R. J., Solomon, D. H., & Kim, S. C. (2023) · Epidemiology · doi:10.1097/ede.0000000000001608 · Cited by 16
Serum uric acid and cardio-renal diseases
Ruilope, L. M., & Pontremoli, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.790803 · Cited by 15
Gout
Rymal, E., & Rizzolo, D. (2014) · JAAPA · doi:10.1097/01.jaa.0000453233.24754.ec · Cited by 15
The vasodilatory effect of allopurinol mediates its antihypertensive effect: Effects on calcium movement and cardiac hemodynamics
El‐Bassossy, H. M., Mahmoud, M. F., & Eid, B. G. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.033 · Cited by 15
Uric acid lowering improves insulin sensitivity and lowers blood pressure: a meta-analysis of randomized parallel-controlled clinical trials
Zong, Q., Ma, G., & Wang, T. (2021) · African Health Sciences · doi:10.4314/ahs.v21i1.13 · Cited by 14
The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis
Barrientos-Regala, M. A., Macabeo, R., Ramirez-Ragasa, R., Pestaño, N. S., Punzalan, F. E. R., Tumanan-Mendoza, B. A., & Castillo, R. R. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000871 · Cited by 15
Serum Uric Acid in Primary Hypertension
Bavishi, C., Messerli, F. H., & Rimoldi, S. F. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07056 · Cited by 14
Self-citation
The effects of topiroxostat on vascular function in patients with hyperuricemia
Higa, S., Shima, D., Tomitani, N., Fujimoto, Y., & Kario, K. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13707 · Cited by 13
A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial
Bakris, G. L., Mikami, H., Hirata, M., Nakajima, A., & Cressman, M. D. (2021) · Kidney360 · doi:10.34067/kid.0001672021 · Cited by 14
Effects of febuxostat on serum urate level in Japanese hyperuricemia patients
Yamamoto, T., Hidaka, Y., Inaba, M., Ishimura, E., Ooyama, H., Kakuta, H., Moriwaki, Y., Higami, K., Ohtawara, A., Hosoya, T., et al. (2015) · Modern Rheumatology · doi:10.3109/14397595.2015.1016257 · Cited by 12
Uric acid and gamma‐glutamyl‐transferase in children and adolescents with obesity: Association to anthropometric measures and cardiometabolic risk markers depending on pubertal stage, sex, degree of weight loss and type of patient care: Evaluation of the adiposity patient follow‐up registry
Blüher, S., Wiegand, S., Weihe, P., Prinz, N., Weghuber, D., Leipold, G., Dannemann, A., Bergjohann, L., Reinehr, T., Holl, R. W., et al. (2022) · Pediatric Obesity · doi:10.1111/ijpo.12989 · Cited by 12
Allopurinol decreases serum uric acid level and intestinal glucose transporter-5 expression in rats with fructose-induced hyperuricemia
Chen, G., & Jia, P. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.04.014 · Cited by 12
Association of hyperuricemia and hypertension phenotypes in hypertensive patients without uric acid lowering treatment
Liu, C., Da, Q., Zhang, M., Hou, J., Lin, J., & Liao, H. (2021) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2021.1907397 · Cited by 12
Biomarkers of Oxidative Stress in Human Hypertension
Tsiropoulou, S., Dulak-Lis, M. G., Montezano, A. C. I., & Touyz, R. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-39599-9_11 · Cited by 11
Pro-inflammatory diets promote the formation of hyperuricemia
Liu, X., Chen, T., Gao, T., Shi, K.-Q., Yin, F.-Q., Yu, Y.-X., & Zhang, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398917 · Cited by 11
Hyperuricemia prevalence in Indian subjects with underlying comorbidities of hypertension and/or type 2 diabetes: a retrospective study from subjects attending hyperuricemia screening camps
Patel, H., & Shah, D. (2020) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20200477 · Cited by 10
Urate-lowering therapy exerts protective effects against hypertension development in patients with gout
Lin, K., Yen, F., Li, H., Wei, J. C., Hsu, C., Yang, C., & Hwu, C. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0342-4 · Cited by 10

Authors: Agarwal, V., Hans, N., & Messerli, F. H.
Affiliations: St. Luke's-Roosevelt Hospital Center (US)
Tufts University (US)
Corresponding author: Messerli, Franz H.
ORCID: Messerli, Franz H.
Venue: The Journal of Clinical Hypertension
Publisher: Wiley
Published: 2012-08-20
Volume: 15
Issue: 6
Pages: 435-442
ISSN: 1524-6175 (ISSN-L)
1751-7176
DOI: 10.1111/j.1751-7176.2012.00701.x
PMC: PMC8033809
OpenAlex: W1516957924
Cited by: 173
References: 33
Citations by year: 2026: 4 · 2025: 8 · 2024: 9 · 2023: 14 · 2022: 17 · 2021: 8 · 2020: 15 · 2019: 17 · 2018: 20 · 2017: 15 · 2016: 17 · 2015: 10 · 2014: 11 · 2013: 8
FWCI: 1.35
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Clinical Hypertension (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
Keywords: allopurinol, blood pressure, xanthine oxidase inhibitors, hyperuricemia, hypertension, systolic blood pressure, diastolic blood pressure, antihypertensive effect
MeSH terms: Allopurinol, Blood Pressure, Gout Suppressants, Humans, Hypertension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks